Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CARA |
---|---|---|
09:32 ET | 7009 | 0.651 |
09:36 ET | 2726 | 0.65825 |
09:38 ET | 792 | 0.67 |
09:39 ET | 200 | 0.677 |
09:43 ET | 1000 | 0.6733 |
09:45 ET | 400 | 0.6766 |
09:48 ET | 4774 | 0.6766 |
09:50 ET | 900 | 0.6766 |
09:52 ET | 400 | 0.6765 |
09:54 ET | 710 | 0.6602 |
09:56 ET | 400 | 0.6766 |
09:57 ET | 510 | 0.6766 |
09:59 ET | 200 | 0.6766 |
10:01 ET | 100 | 0.6767 |
10:03 ET | 18351 | 0.6644 |
10:06 ET | 635 | 0.6602 |
10:08 ET | 100 | 0.6686 |
10:10 ET | 200 | 0.6686 |
10:14 ET | 100 | 0.6689 |
10:15 ET | 700 | 0.6699 |
10:17 ET | 3259 | 0.675 |
10:19 ET | 200 | 0.6749 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Cara Therapeutics Inc | 36.8M | -0.3x | --- |
ImmuCell Corp | 33.5M | -8.6x | --- |
Aadi Bioscience Inc | 42.7M | -0.7x | --- |
Turnstone Biologics Corp | 62.7M | -0.8x | --- |
SQZ Biotechnologies Co | 1.1M | 0.0x | --- |
Prenetics Global Ltd | 72.8M | -1.2x | --- |
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $36.8M |
---|---|
Revenue (TTM) | $16.9M |
Shares Outstanding | 54.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.77 |
EPS | $-2.26 |
Book Value | $1.05 |
P/E Ratio | -0.3x |
Price/Sales (TTM) | 2.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -729.19% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.